{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"190"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"215"}],"units":"Participants"}],"groups":[{"description":"Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as an infusion with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.\n\nPalonosetron\n\nDexamethasone","id":"OG000","title":"I.V. Palonosetron Infusion Plus Dexamethasone"},{"description":"Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as a bolus with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.\n\nPalonosetron\n\nDexamethasone","id":"OG001","title":"I.V. Palonosetron Bolus Plus Dexamethasone"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"0-24 hours","title":"Percentage of Patients With no Emetic Episodes in the Acute Phase","type":"SECONDARY","unitOfMeasure":"Participants"}